Navigation Links
Risk assessment tool not reliable predictor for some women at high risk of breast cancer
Date:11/5/2008

ROCHESTER, Minn. -- A statistical model commonly used to predict the risk of breast cancer in women was not accurate when used to evaluate women with atypical hyperplasia, according to a new Mayo Clinic study published in the Oct. 14, 2008, issue of the Journal of Clinical Oncology. Atypical hyperplasia (atypia) describes breast tissue with an increased growth of abnormal cells that might become cancerous.

The Gail model calculates probabilities that a woman will develop invasive breast cancer during the next five years, and by age 90. The model has come to be called by the name of its developer, National Cancer Institute researcher Mitchell Gail, M.D., Ph.D. Its original purpose was to identify groups of high-risk women for participation in breast cancer chemoprevention studies. But the model has since been used in clinical settings to counsel individuals about their risk of developing breast cancer. Predicting risk at an individual level is much more challenging than when risks can be averaged across groups.

"The assumption has always been that this model works well in women with atypia, but this had never been validated," says Shane Pankratz, Ph.D., Mayo Clinic statistician and a lead investigator in the study. "We found that, for the group of women with atypia, the model predicted significantly fewer invasive breast cancers than were actually observed, and we also observed that the model was not able to reliably identify the women who were actually at higher risk of developing breast cancer."

The Gail model considers the woman's family history of breast cancer, her age, and her ages at the onset of menstruation and at first live birth, as well as the number of breast biopsies undergone and presence of atypical hyperplasia found in biopsies. About 5 percent of women who undergo biopsies for suspicious lumps or other breast concerns have atypia. About 25 percent of those with atypia will develop cancer within 25 years.

Mayo Clinic researchers tested the Gail model in 331 women with atypia who had benign breast biopsies at Mayo Clinic between 1967 and 1991. Of these women, 58 developed cancer during an average of 13.7 years of follow-up. In contrast, the model predicted that 34.9 women would develop breast cancer in that period.

Using these and other data, researchers also calculated the model's performance for individuals using the concordance statistic (c-statistic), which reflects how closely the actual timing of breast cancer events aligned with model predictions. A c-statistic of 0.5 is observed if the predictions are no better than random chance; a c-statistic of 1.0 is observed if the predictions are perfectly concordant with the actual outcomes. In this study, the c-statistic was 0.5, reflecting that the Gail model worked no better than a coin flip in predicting which of the women with atypia would develop invasive breast cancer.

When assessed across other groups of women without respect to the presence of atypia, the Gail model typically performs better. In that setting, it has been shown to predict approximately the same number of breast cancers that later occur.

Lynn Hartmann, M.D., Mayo Clinic oncologist and co-investigator on the study, says that there is strong interest in predicting breast cancer risk. For example, the Gail model, posted on the National Cancer Institute's Web site (http://www.cancer.gov/bcrisktool/), attracts 25,000 viewers each month.

"Doctors counsel women at high risk to have more frequent or intensive surveillance or to consider chemoprevention strategies such as tamoxifen or raloxifene," says Dr. Hartmann. "When making such decisions, women and their physicians must have highly reliable risk estimates."

Researchers are pursuing other avenues to better predict individual risk. Previously, Mayo Clinic researchers found that women with multiple sites of cellular atypia in a breast biopsy have significantly increased risk of developing breast cancer. In a study published earlier this year, Mayo researchers found that women whose atypia tissues express COX-2 enzymes were more likely to develop breast cancer, and the higher the COX-2 levels, the higher the risk.


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
2. Personality can hamper a physicians assessment of depression
3. Simple, inexpensive and objective tools for the assessment of mucosal inflammation: fecal markers
4. California Dental Association Foundation Launches New Dental Risk Assessment Campaign
5. Notice of Proposed Rulemaking on U.S. Department of Labors Risk Assessment Procedures Published in Federal Register
6. DIA Conference to Provide New Paradigms in Evidence-Based Medicine and Health Technology Assessment
7. Risk assessment plays key role in long-term treatment of breast cancer
8. InfoLogix Launches Strategic Mobility Assessment Service for Hospitals
9. The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals
10. Fox Learning Systems Selects Prymaks Discovery-180(TM) Technology Assessment to Guide Search for New LMS
11. Combined Insurance Provides Needs Assessment Checklist to Help Consumers Evaluate Their Current Supplemental Health Insurance Coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... $3,296 in property taxes a year. In some states—like New York, New Jersey, ... By contrast, many overseas retirement havens have extremely low property-tax rates, which contributes ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: